GOSS
Gossamer Bio, Inc.
A clinical-stage biopharmaceutical company based in San Diego, Gossamer Bio develops treatments for rare diseases like pulmonary arterial hypertension (PAH), a progressive condition of high blood pressure in the lungs. Its lead drug candidate, seralutinib, is an inhaled dry-powder medicine designed to be breathed directly into the lungs. Founded in 2015, the company takes its name from the gossamer thread, meant to symbolize the fragile yet vital connections it builds with patients and partners.
CUSIP: 38341P102HealthcareUS1 holder
Recent Activity
2019Q4
1 sell
-967.2K shares
-967.2K shares
2019Q3
1 sell
-300.0K shares(-23.7%)
-300.0K shares(-23.7%)
2019Q1
1 buy
+1.27M shares
+1.27M shares